Sign in or create an account to add this stock to your watchlist.
About Sunesis Pharmaceuticals (NASDAQ:SNSS)
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies. The company also engages in developing TAK-580, a pan-Raf inhibitor program in combination with various anticancer agents for the treatment of advanced solid tumor cancers in adult patients; SNS-510, which is in preclinical pharmacology and toxicology studies for the treatment of solid tumor and hematologic malignancies; and vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). In addition, it is developing vosaroxin, which is in Phase 2 trial with decitabine for treatment of diagnosed acute AML or myelodysplastic syndrome (MDS); Phase 1/2 trial with azacitidine for treatment of MDS; Phase 2 trial with infusional cytarabine for treatment of AML; Phase 1/2 trial in adult patients with previously treated intermediate-2 or high-risk MDS; and Phase 1/2 trial with cytarabine tested as consolidation therapy. The company has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of phosphoinositide-dependent kinase-1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:SNSS
CUSIP86732860
Phone650-266-3500
Debt
Debt-to-Equity RatioN/A
Current Ratio2.31
Quick Ratio2.31
Price-To-Earnings
Trailing P/E Ratio-1.88
Forward P/E Ratio-2.79
P/E GrowthN/A
Sales & Book Value
Annual Sales$670,000.00
Price / Sales139.02
Cash FlowN/A
Price / CashN/A
Book Value$0.02 per share
Price / Book135.50
Profitability
EPS (Most Recent Fiscal Year)($1.45)
Net Income$-35,450,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-129.91%
Miscellaneous
Employees34
Outstanding Shares34,370,000
Sunesis Pharmaceuticals (NASDAQ:SNSS) Frequently Asked Questions
What is Sunesis Pharmaceuticals' stock symbol?
Sunesis Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNSS."
How were Sunesis Pharmaceuticals' earnings last quarter?
Sunesis Pharmaceuticals (NASDAQ:SNSS) released its quarterly earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.27) by $0.06. The biopharmaceutical company had revenue of $0.24 million for the quarter. View Sunesis Pharmaceuticals' Earnings History.
What price target have analysts set for SNSS?
5 brokerages have issued 12 month price objectives for Sunesis Pharmaceuticals' shares. Their forecasts range from $2.48 to $7.00. On average, they expect Sunesis Pharmaceuticals' share price to reach $4.4933 in the next year. View Analyst Ratings for Sunesis Pharmaceuticals.
What are Wall Street analysts saying about Sunesis Pharmaceuticals stock?
Here are some recent quotes from research analysts about Sunesis Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. " (5/10/2018)
- 2. Cantor Fitzgerald analysts commented, "SNS-062 Data Now 3Q18. SNSS disclosed that it now expects to complete the Phase Ib trial of SNS-062 in fall 2018, which we interpret as early 4Q18, though it could be late 3Q18. The second dose cohort (50 mg) has not yet completed, but since a Phase Ia in healthy volunteers was run, our expectation has been that it would not take many doses to identify the Phase II dose (RP2D). While the reasons for the delay (rapidly progressing patient, non-drug related AE) are understandable, we think the disclosure could cause the shares to pull back." (3/8/2018)
- 3. Cowen Inc analysts commented, "Sunesis reported Q3 Net loss of $9.9MM and pro forma September 30 cash of." (11/2/2017)
Who are some of Sunesis Pharmaceuticals' key competitors?
Some companies that are related to Sunesis Pharmaceuticals include Evolus (EOLS), Paratek Pharmaceuticals (PRTK), Corbus Pharmaceuticals (CRBP), Strongbridge Biopharma (SBBP), Unum Therapeutics (UMRX), Bellicum Pharmaceuticals (BLCM), Catalyst Pharmaceuticals (CPRX), Athersys (ATHX), Catalyst Biosciences (CBIO), Arbutus Biopharma (ABUS), ArQule (ARQL), Corium International (CORI), Corvus Pharmaceuticals (CRVS), Seres Therapeutics (MCRB) and DURECT (DRRX).
Who are Sunesis Pharmaceuticals' key executives?
Sunesis Pharmaceuticals' management team includes the folowing people:
- Mr. Dayton Misfeldt, Interim CEO & Director (Age 44)
- Mr. Daniel N. Swisher Jr., Strategic Advisor (Age 55)
- Mr. William P. Quinn, CFO and Sr. VP of Fin. & Corp. Devel.
- Mr. Gene C. Jamieson, VP of Technical Operations
- Dr. Judith A. Fox Ph.D., Chief Scientific Officer
Has Sunesis Pharmaceuticals been receiving favorable news coverage?
Media stories about SNSS stock have trended somewhat positive this week, according to Accern. Accern ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Sunesis Pharmaceuticals earned a news sentiment score of 0.09 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 47.37 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are Sunesis Pharmaceuticals' major shareholders?
Sunesis Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (4.90%), DAFNA Capital Management LLC (1.09%), Millennium Management LLC (0.31%), Spark Investment Management LLC (0.22%) and Wells Fargo & Company MN (0.19%). Company insiders that own Sunesis Pharmaceuticals stock include Dayton Misfeldt, Geoffrey M Parker and Mpm Oncology Impact Management. View Institutional Ownership Trends for Sunesis Pharmaceuticals.
Which institutional investors are selling Sunesis Pharmaceuticals stock?
Which institutional investors are buying Sunesis Pharmaceuticals stock?
SNSS stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Spark Investment Management LLC and Wells Fargo & Company MN. Company insiders that have bought Sunesis Pharmaceuticals stock in the last two years include Dayton Misfeldt, Geoffrey M Parker and Mpm Oncology Impact Management. View Insider Buying and Selling for Sunesis Pharmaceuticals.
How do I buy shares of Sunesis Pharmaceuticals?
Shares of SNSS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sunesis Pharmaceuticals' stock price today?
One share of SNSS stock can currently be purchased for approximately $2.71.
How big of a company is Sunesis Pharmaceuticals?
Sunesis Pharmaceuticals has a market capitalization of $95.21 million and generates $670,000.00 in revenue each year. The biopharmaceutical company earns $-35,450,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis. Sunesis Pharmaceuticals employs 34 workers across the globe.
How can I contact Sunesis Pharmaceuticals?
Sunesis Pharmaceuticals' mailing address is 395 OYSTER POINT BOULEVARD SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-266-3500 or via email at [email protected]
MarketBeat Community Rating for Sunesis Pharmaceuticals (SNSS)
MarketBeat's community ratings are surveys of what our community members think about Sunesis Pharmaceuticals and other stocks. Vote "Outperform" if you believe SNSS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNSS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Sunesis Pharmaceuticals (NASDAQ:SNSS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Sunesis Pharmaceuticals (NASDAQ SNSS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 7.53%
Institutional Ownership Percentage: 51.94%
Sunesis Pharmaceuticals (NASDAQ SNSS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/6/2017 | Mpm Oncology Impact Management | Major Shareholder | Buy | 81,500 | $2.77 | $225,755.00 | |  |
| 11/2/2017 | Mpm Oncology Impact Management | Major Shareholder | Buy | 25,300 | $2.59 | $65,527.00 | | |
| 10/27/2017 | Dayton Misfeldt | Director | Buy | 400,000 | $2.00 | $800,000.00 | | |
| 12/9/2016 | Geoffrey M Parker | Director | Buy | 3,740 | $3.87 | $14,473.80 | 65,151 | |
| 5/26/2016 | Geoffrey M Parker | Director | Buy | 9,500 | $0.47 | $4,465.00 | 62,005 | |
| 5/25/2016 | Geoffrey M Parker | Director | Buy | 52,505 | $0.47 | $24,677.35 | 30,000 | |
| 12/21/2015 | Dayton Misfeldt | Director | Buy | 1,750,000 | $0.84 | $1,470,000.00 | | |
| 8/25/2015 | Daniel N Swisher Jr | CEO | Buy | 12,216 | $1.01 | $12,338.16 | 179,510 | |
| 8/24/2015 | Daniel N Swisher Jr | CEO | Buy | 12,784 | $1.01 | $12,911.84 | 179,510 | |
| 8/29/2014 | Forest Baskett | Major Shareholder | Sell | 266,700 | $7.97 | $2,125,599.00 | | |
| 8/28/2014 | Bay City Capital Llc | Major Shareholder | Sell | 300,700 | $7.98 | $2,399,586.00 | | |
| 8/28/2014 | Dayton Misfeldt | Director | Sell | 200,000 | $7.89 | $1,578,000.00 | | |
| 8/27/2014 | Adam R Craig | CMO | Sell | 2,554 | $8.00 | $20,432.00 | | |
| 8/27/2014 | Daniel N Swisher Jr | CEO | Sell | 5,000 | $8.00 | $40,000.00 | | |
| 8/27/2014 | Dayton Misfeldt | Director | Sell | 100,700 | $8.16 | $821,712.00 | | |
| 8/27/2014 | Eric Bjerkholt | CFO | Sell | 10,000 | $8.00 | $80,000.00 | | |
| 8/27/2014 | Krishna Kittu Kolluri | Major Shareholder | Sell | 108,300 | $8.17 | $884,811.00 | | |
| 8/12/2014 | Dayton Misfeldt | Director | Sell | 743,700 | $6.64 | $4,938,168.00 | | |
| 8/12/2014 | Equity Opportunities Fu Growth | Major Shareholder | Sell | 710,540 | $6.63 | $4,710,880.20 | | |
(Data available from 1/1/2013 forward)
Sunesis Pharmaceuticals (NASDAQ SNSS) News Headlines
| Source: |
|
Sunesis Pharmaceuticals (NASDAQ:SNSS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Sunesis Pharmaceuticals (NASDAQ:SNSS) Income Statement, Balance Sheet and Cash Flow Statement
Sunesis Pharmaceuticals (NASDAQ SNSS) Stock Chart for Monday, May, 21, 2018
Loading chart…
